Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations

Bibliography

• Elder DP. Effective formulation development strategies for poorly soluble active pharmaceutical ingredients (APIs). Pharm Outsourcing 2011;12(2):56–6
   Google Scholar
• Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm 2012;2012:195727
   PubMedGoogle Scholar
• Lipinski CA. Drug-like properties and the cause of poor solubility and permeability. J Pharmacol Toxicol Methods 2000;44:235–49
   PubMed Web of Science ®Google Scholar
• Vemula VR, Lagishetty V, Lingala S. Solubility enhancement techniques. Int J Pharm Sci Rev Res 2010;5:41–51
   PubMedGoogle Scholar
• Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413–20
   PubMed Web of Science ®Google Scholar
• Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world’s top oral drugs. AAPS J 2009;11:740–6
   PubMed Web of Science ®Google Scholar
• Chen ML, Amidon GL, Benet LZ, et al. The BCS, BDDCS, and regulatory guidances. Pharm Res 2011;28:1774–8
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11–23
   PubMed Web of Science ®Google Scholar
• Butler JM, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci 2010;99:4940–54
   PubMed Web of Science ®Google Scholar
• Williams HD, Trevaskis NL, Charman SA, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev 2013;65:315–499
   PubMed Web of Science ®Google Scholar
• Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv 2007;403–16
   PubMed Web of Science ®Google Scholar
• Joshi VY, Sawant MR. Study on dissolution rate enhancement of poorly water soluble drug: contributions of solubility enhancement and relatively low micelle diffusivity. J Disper Sci Technol 2006;27:1141–50
   Web of Science ®Google Scholar
• Qiang D, Gunn JA, Schultz L, Li ZJ. Evaluation of the impact of sodium lauryl sulfate source variability on solid oral dosage form development. Drug Dev Ind Pharm 2010;36:1486–96
   PubMed Web of Science ®Google Scholar
• Duchene D, Wouessidjewe D, Ponchel G. Cyclodextrins and carrier systems. J Controll Release 1999;62:263–8
   PubMed Web of Science ®Google Scholar
• Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull [Tokyo] 2004;52:900–15
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003;18:113–20
   PubMed Web of Science ®Google Scholar
• Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Inter J Pharm 1998;160:229–37
   Web of Science ®Google Scholar
• Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm 2013;453:198–214
   PubMed Web of Science ®Google Scholar
• Kiriyama A, Iga K, Shibata N. Availability of polymeric nanoparticles for specific enhanced and targeted drug delivery. Therap Deliv 2013;4:1261–78
   PubMedGoogle Scholar
• Chilajwar SV, Pednekar PP, Jadhav KR, et al. Cyclodextrin-based nanosponges: a propitious platform for enhancing drug delivery. Expert Opin Drug Deliv 2014;11:111–20
   PubMed Web of Science ®Google Scholar
• Shegokar R. Nanosuspensions: a new approach for organ and cellular targeting in infectious diseases. J Pharm Invest 2013;43:1–26
   Google Scholar
• Sutradhar KB, Khatun S, Luna IP. Increasing possibilities of nanosuspension. J Nanotechnol 2013;2013:1–12
   Google Scholar
• Zhai X, Lademann J, Keck CM, et al. Nanocrystals of medium soluble actives–novel concept for improved dermal delivery and production strategy. Int J Pharm 2014;470:141–50
   PubMed Web of Science ®Google Scholar
• Tsai N, Lee B, Kim A, et al. Nanomedicine for global health. J Lab Autom 2014;19:511–16
   Google Scholar
• Junghanns J, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 2008;3:295–309
   PubMed Web of Science ®Google Scholar
• Prabhakar C, Krishna KB. A review of nanosuspension in drug delivery. Int J Pharm Bio Sci 2011;2:549–58
   Google Scholar
• Rao GC, Kumar MS, Mathivanan N, et al. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie 2004;59:5–9
   PubMed Web of Science ®Google Scholar
• Hörter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Delivery Rev 2001;46:75–87
   PubMed Web of Science ®Google Scholar
• Cavalli R, Leone F. Nanosuspension: a versatile drug delivery platform. Chemistry Today 2013;31:46–9
   Google Scholar
• Jinno J, Kamada N, Miyake M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Controll Release 2006;111:56–64
   PubMed Web of Science ®Google Scholar
• Lenhardt T, Vergnault G, Grenier P, et al. Evaluation of nanosuspensions for absorption enhancement of poorly soluble drugs: in vitro transport studies across intestinal epithelial monolayers. AAPS J 2008;10:435–8
   PubMed Web of Science ®Google Scholar
• Ponchel G, Montisci M, Dembri A. Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur J Pharm Biopharm 1997;4:25–31
   Web of Science ®Google Scholar
• Tur KM, Ch’ng H-S. Evaluation of possible mechanism[s] of bioadhesion. Inter J Pharm 1998;160:61–74
   Google Scholar
• Müller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation,optimisation and long-term stability. Inter J Pharma 2002;237:151–61
   PubMed Web of Science ®Google Scholar
• Henriksen I, Green KL, Smart JD, et al. Bioadhesion of hydrated chitosans: an in vitro and in vivo study. Int J Pharm 1996;145:231–40
   Web of Science ®Google Scholar
• Lueßen HL, Rentel C-O, Kotzé AF, et al. Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and Chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J Control Release 1997;45:15–23
   Web of Science ®Google Scholar
• Cavalli R. Nanosuspension technology: a versatile drug delivery platform. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; Lisbona (Portugal): 2014
   Google Scholar
• Chan HK, Kwok PC. Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliv Rev 2011;63:406–16
   PubMed Web of Science ®Google Scholar
• Sinha B, Muller RH, Moschwitzer JP. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm 2013;453:126–41
   PubMed Web of Science ®Google Scholar
• Couvreur P. Drug delivery: Replenishing reservoirs in vivo. Nat Nanotechnol 2014;9:874–5
   PubMed Web of Science ®Google Scholar
• LaMer VK, Dinegar RH. Theory, production and mechanism of formation of monodispersed hydrosols. J Am Chem Soc 1950;72:4847–54
   Web of Science ®Google Scholar
• Hua T-T, Wanga J-X, Shena Z-G, Chen J-F. Engineering of drug nanoparticles by HGCP for pharmaceutical applications. Particuology 2008;6:239–51
   Web of Science ®Google Scholar
• Johnson BK, Prud’homme RK. Flash nanoprecipitation of organic actives and block copolymers using a confined impinging jets mixer. Aust J Chem 2003;56:1021–4
   Web of Science ®Google Scholar
• Liu Y, Cheng C, Liu Y, et al. Mixing in a multi-inlet vortex mixer [MIVM] for flash nano-precipitation Chem Eng Sci. 2008;63:2829–42
   Google Scholar
• Byrappa K, Ohara S, Adschiri T. Nanoparticles synthesis using supercritical fluid technology - towards biomedical applications. Adv Drug Deliv Rev 2008;60:299–327
   PubMed Web of Science ®Google Scholar
• Luque de Castro MD, Priego-Capote F. Ultrasound-assisted crystallization [sonocrystallization] Ultrason Sonochem. 2007;14:717–24
   Google Scholar
• Tran TT, Tran PH, Nguyen MN, et al. Amorphous isradipine nanosuspension by the sonoprecipitation method. Int J Pharm 2014;474:146–50
   PubMed Web of Science ®Google Scholar
• Vitale SA, Katz JL. Liquid droplet dispersions formed by homogeneous liquid-liquid nucleation: “The Ouzo Effect”. Langmuir 2003;19:4105–10
   Web of Science ®Google Scholar
• Lepeltier E, Bourgaux C, Couvreur P. Nanoprecipitation and the “Ouzo effect”: Application to drug delivery devices. Adv Drug Deliv Rev 2014;71:86–97
   PubMed Web of Science ®Google Scholar
• Masters K. Spray drying handbook. New York, NY: 1979
   Google Scholar
• Eerikäinen H, Watanabe W, Kauppinen EI, et al. Aerosol flow reactor method for synthesis of drug nanoparticles. Eur J Pharm Biopharm 2003;55:357–60
   PubMed Web of Science ®Google Scholar
• Sridhar R, Ramakrishna S. Electrosprayed nanoparticles for drug delivery and pharmaceutical applications. Biomatter 2013;3:1–12
   Google Scholar
• Trotta M, Gallarate M, Pattarino F, Morel S. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J Controll Release 2001;76:119–28
   PubMed Web of Science ®Google Scholar
• Trotta M, Gallarate M, Carlotti ME, Morel S. Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. Int J Pharm 2003;254:235–42
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev 2011;63:427–40
   PubMed Web of Science ®Google Scholar
• van Hoogevest P, Liu X, Fahr A. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective. Expert Opin Drug Deliv 2011;8:1481–500
   PubMed Web of Science ®Google Scholar
• Kayser O. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Inter J Pharm 2001;214:83–5
   PubMed Web of Science ®Google Scholar
• Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol 2010;62:1569–79
   PubMed Web of Science ®Google Scholar
• Müller RH, Möschwitzer J, Nadiem B. Manufacturing of Nanoparticles by Milling and Homogenization Techniques. Nanoparticle Technology for Drug Delivery. Taylor & Francis Group; New York: 2006
   Google Scholar
• Sharma S, Verma A, Teja BV. Nanoparticle Technology for Drug Delivery. Development of stabilized Paclitaxel nanocrystals: In-vitro and in-vivo efficacy studies. Eur J Pharm Sci 2015;69:51–60
   PubMed Web of Science ®Google Scholar
• Keck CM, Muller RH, et al. Second generation of drug nanocrystals for Delivery of poorly soluble drugs : Smart crystals technology. DOSIS 2008;24:124–28
   Google Scholar
• Müller RHJ, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future. Adv Drug Delivery Rev 2001;47:3–19
   PubMed Web of Science ®Google Scholar
• Morakul B, Suksiriworapong J, Chomnawang MT, et al. Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method. Eur J Pharm Biopharm 2014;88:886–96
   PubMed Web of Science ®Google Scholar
• Keck C, Kobierski S, Mauludin R, et al. Second generation of drug nanocrystals for delivery of poorly soluble drugs : smart crystals technology. DOSIS 2008;24:124–8
   Google Scholar
• Shaal LA, Müller RH. Shegokar R. smartCrystal combination technology – scale up from lab to pilot scale and long term stability. Pharmazie 2010;65:877–84
   PubMed Web of Science ®Google Scholar
• Fischer HC, Chan WC. Nanotoxicity: the growing need for in vivo study. Curr Opin Biotechnol 2007;18:565–71
   PubMed Web of Science ®Google Scholar
• Grainger DW. Nanotoxicity assessment: all small talk? Adv Drug Deliv Rev 2009;61:419–21
   PubMed Web of Science ®Google Scholar
• Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev 2011;63:456–69
   PubMed Web of Science ®Google Scholar
• Troester F. editor. Cremophor- free aqueous paclitaxel nanosuspension - production and chemical stability. Controlled release society 31st annual meeting; Honolulu – HI; 12 – 16 June;2004
   Google Scholar
• Strydom SJ, Otto DP, Stieger N, et al. Self-assembled macromolecular nanocoatings to stabilize and control drug release from nanoparticles. Powder Technol 2014;256:470–6
   Web of Science ®Google Scholar
• Willart JF, Descamps M. Solid state amorphization of pharmaceuticals. Mol Pharm 2008;5:905–20
   PubMed Web of Science ®Google Scholar
• Kayaert P, Anne M, Van den Mooter G. Bead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in-vitro release from sugar beads. J Pharm Pharmacol 2011;63:1446–53
   PubMed Web of Science ®Google Scholar
• Wu T, Sun Y, Li N, et al. Inhibiting Surface Crystallization of Amorphous Indomethacin by Nanocoating. Langmuir 2007;23:5148–53
   PubMed Web of Science ®Google Scholar
• Willart JF, Dujardin N, Dudognon E, et al. Amorphization of sugar hydrates upon milling. Carbohydr Res 2010;345:1613–16
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B, Vermant J, Martens JA, et al. A screening study of surface stabilization during the production of drug nanocrystals. J Pharm Sci 2009;98:2091–103
   PubMed Web of Science ®Google Scholar
• Ochi M, Kawachi T, Toita E, et al. Development of nanocrystal formulation of meloxicam with improved dissolution and pharmacokinetic behaviors. Int J Pharm 2014;474:151–6
   PubMed Web of Science ®Google Scholar
• Chauhan H, Hui-Gu C, Atef E. Correlating the behavior of polymers in solution as precipitation inhibitor to its amorphous stabilization ability in solid dispersions. J Pharm Sci 2013;102:1924–35
   PubMed Web of Science ®Google Scholar
• Mauludin R, Muller RH, Keck CM. Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur J Pharm Biopharm 2009;36:502–10
   Web of Science ®Google Scholar
• Hao L, Wang X, Zhang D, et al. Studies on the preparation, characterization and pharmacokinetics of Amoitone B nanocrystals. Int J Pharm 2012;433:157–64
   PubMed Web of Science ®Google Scholar
• Lee J, Lee SJ, Choi JY, et al. Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur J Pharm Biopharm 2005;24:441–9
   Web of Science ®Google Scholar
• Hong C, Dang Y, Lin G, et al. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: An in vitro and in vivo evaluation. Int J Pharm 2014;477:251–60
   PubMed Web of Science ®Google Scholar
• Moschwitzer J, Muller RH. Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur J Pharm Biopharm 2006;62:282–7
   PubMed Web of Science ®Google Scholar
• Cerdeira AM, Mazzotti M, Gander B. Formulation and drying of miconazole and itraconazole nanosuspensions. Int J Pharm 2013;443:209–20
   PubMed Web of Science ®Google Scholar
• Kumar S, Jog R, Shen J, et al. Formulation and Performance of Danazol Nano-crystalline Suspensions and Spray Dried Powders. Pharm Res 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Kumar S, Gokhale R, Burgess DJ. Sugars as bulking agents to prevent nano-crystal aggregation during spray or freeze-drying. Int J Pharm 2014;471:303–11
   PubMed Web of Science ®Google Scholar
• Yue P, Wang C, Dan J, et al. The importance of solidification stress on the redispersibility of solid nanocrystals loaded with harmine. Int J Pharm 2015;480:107–15
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 2012;52:481–503
   PubMed Web of Science ®Google Scholar
• Zolnik BS, Sadrieh N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv Drug Deliv Rev 2009;61:422–7
   PubMed Web of Science ®Google Scholar
• Pawar VK, Singh Y, Meher JG, et al. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery. J Controll Release 2014;183:51–66
   PubMed Web of Science ®Google Scholar
• Müller RH, Gohla S, Keck CM. State of the art of nanocrystals–special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 2011;78:1–9
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283–318
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005;19:311–30
   PubMed Web of Science ®Google Scholar
• Lundqvist M, Stigler J, Elia G, et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad of Sci USA 2008;105:14265–70
   PubMed Web of Science ®Google Scholar
• Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv 2011;8:343–57
   PubMed Web of Science ®Google Scholar
• Monopoli MP, Walczyk D, Campbell A, et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 2011;133:2525–34
   PubMed Web of Science ®Google Scholar
• Hamad I, Al-Hanbali O, Hunter AC, et al. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 2010;4:6629–38
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003;42:463–78
   PubMed Web of Science ®Google Scholar
• Jang K, Yoon S, Kim SE, et al. Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state. Drug Des Devel Ther 2014;8:851–8
   PubMed Web of Science ®Google Scholar
• Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Inter J Pharm 1995;125:91–7
   Web of Science ®Google Scholar
• Liversidge GG, Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Inter J Pharm 1995;125:309–13
   Web of Science ®Google Scholar
• Mauludin R, Muller RH, Keck CM. Development of an oral rutin nanocrystal formulation. Int J Pharm 2009;370:202–9
   PubMed Web of Science ®Google Scholar
• Sahoo NG, Kakran M, Shaal LA, et al. Preparation and characterization of quercetin nanocrystals. J Pharm Sci 2011;100:2379–90
   PubMed Web of Science ®Google Scholar
• Kayser O. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003;254:73–5
   PubMed Web of Science ®Google Scholar
• Patel K, Patil A, Mehta M. Oral delivery of paclitaxel nanocrystal [PNC] with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity. Int J Pharm 2014;472:214–23
   PubMed Web of Science ®Google Scholar
• Rabinow B, Kipp J, Papadopoulos P, et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 2007;339:251–60
   PubMed Web of Science ®Google Scholar
• Moschwitzer J, Achleitner G, Pomper H, et al. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 2004;58:615–19
   PubMed Web of Science ®Google Scholar
• Danhier F, Ucakar B, Vanderhaegen ML, et al. Nanosuspension for the delivery of a poorly soluble anti-cancer kinase inhibitor. Eur J Pharm Biopharm 2014;88:252–60
   PubMed Web of Science ®Google Scholar
• Liu G, Zhang D, Jiao Y, et al. In vitro and in vivo evaluation of riccardin D nanosuspensions with different particle size. Colloids Surf B Biointerfaces 2013;102:620–6
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang D, Duan C, et al. Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery. J Microencapsul 2012;29:194–203
   PubMed Web of Science ®Google Scholar
• Wang Y, Li X, Wang L, et al. Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. Int J Nanomedicine 2011;6:1497–507
   PubMed Web of Science ®Google Scholar
• Barle EL, Cerne M, Peternel L, et al. Reduced intravenous toxicity of amiodarone nanosuspension in mice and rats. Drug Chem Toxicol 2013;36:263–9
   PubMed Web of Science ®Google Scholar
• Wiedmann TS, DeCastro L, Wood RW. Nebulization of NanoCrystals: production of a respirable solid-in-liquid-in-air colloidal dispersion. Pharm Res 1997;14:112–16
   PubMed Web of Science ®Google Scholar
• Ostrander KD, Bosch HW, Bondanza DM. An in-vitro assessment of a NanoCrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur J Pharm Biopharm 1999;48:207–15
   PubMed Web of Science ®Google Scholar
• Ali HS, York P, Blagden N. Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int J Pharm 2009;375:107–13
   PubMed Web of Science ®Google Scholar
• Jacobs C, Muller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002;19:189–94
   PubMed Web of Science ®Google Scholar
• Duret C, Wauthoz N, Sebti T, et al. New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. Int J Nanomedicine 2012;7:5475–89
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu L, Chan HK, et al. Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev 2011;63:441–55
   PubMed Web of Science ®Google Scholar
• Kobierski S, Ofori-Kwakye K, Müller RH, et al. Resveratrol nanosuspensions for dermal application - production, characterization, and physical stability. Pharmazie 2009;64:741–7
   PubMed Web of Science ®Google Scholar
• Shaal LA, Mishra PR, Müller RH, et al. Nanosuspensions of hesperetin: preparation and characterization. Pharmazie 2014;69:173–82
   PubMed Web of Science ®Google Scholar
• Luschmann C, Herrmann W, Strauss O, et al. Ocular delivery systems for poorly soluble drugs: an in-vivo evaluation. Int J Pharm 2013;455:331–7
   PubMed Web of Science ®Google Scholar
• Kim J, Jang S, Han S, et al. Development of a novel ophtalmic ciclosporin A-loaded nanosuspension using top-down media milling methods. Pharmazie 2011;66:491–5
   PubMed Web of Science ®Google Scholar
• Ahuja M, Dhake AS, Sharma SK, et al. Diclofenac-loaded Eudragit S100 nanosuspension for ophthalmic delivery. J Microencapsul 2011;28:37–45
   PubMed Web of Science ®Google Scholar
• Zhai X, Lademann J, Keck CM, et al. Dermal nanocrystals from medium soluble actives - physical stability and stability affecting parameters. Eur J Pharm Biopharm 2014;88:85–91
   PubMed Web of Science ®Google Scholar
• Rizzo LY, Theek B, Storm G, et al. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol 2013;24(6):1159–66
   PubMed Web of Science ®Google Scholar
• Liu F, Park JY, Zhang Y, et al. Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci 2010;99:3542–51
   PubMed Web of Science ®Google Scholar
• Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010;21:797–802
   PubMed Web of Science ®Google Scholar
• Wang L, Liu Z, Liu D, et al. Docetaxel-loaded-lipid-based-nanosuspensions [DTX-LNS]: preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm 2011;413:194–201
   PubMed Web of Science ®Google Scholar
• Shubar HM, Dunay IR, Lachenmaier S, et al. The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis. J Drug Target 2009;17:257–67
   PubMed Web of Science ®Google Scholar
• Shubar HM, Lachenmaier S, Heimesaat MM, et al. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers. J Drug Target 2011;19:114–24
   PubMed Web of Science ®Google Scholar
• Shegokar R, Singh KK. Surface modified nevirapine nanosuspensions for viral reservoir targeting: in vitro and in vivo evaluation. Int J Pharm 2011;421:341–52
   PubMed Web of Science ®Google Scholar
• de Villiers MM, Otto DP, Strydom SJ, Lvov YM. Introduction to nanocoatings produced by layer-by-layer [LbL] self-assembly. Adv Drug Deliv Rev 2011;63:701–15
   PubMed Web of Science ®Google Scholar
• Zahr AS, de Villiers M, Pishko MV. Encapsulation of drug nanoparticles in self-assembled macromolecular nanoshells. Langmuir 2005;21:403–10
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751–60
   PubMed Web of Science ®Google Scholar
• Fuhrmann K, Gauthier MA, Leroux JC. Crosslinkable polymers for nanocrystal stabilization. J Controll Release 2010;148:e12–13
   PubMed Web of Science ®Google Scholar
• Puligujja P, Balkundi SS, Kendrick LM, et al. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials 2015;41:141–50
   PubMed Web of Science ®Google Scholar
• Fuhrmann K, Gauthier MA, Leroux JC. Targeting of injectable drug nanocrystals. Mol Pharm 2014;11:1762–71
   PubMed Web of Science ®Google Scholar
• Hollis CP, Weiss HL, Leggas M, et al. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Controll Release 2013;172(1):12–21
   PubMed Web of Science ®Google Scholar
• Gao L, Liu G, Ma J, et al. Drug nanocrystals: in vivo performances. J Controll Release 2012;160:418–30
   PubMed Web of Science ®Google Scholar
• Roger E, Lagarce F, Garcion E, et al. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine 2010;5:287–306
   PubMed Web of Science ®Google Scholar
• Muller RH, Keck CM. Twenty years of drug nanocrystals: where are we, and where do we go? Eur J Pharm Biopharm 2012;80:1–3
   PubMed Web of Science ®Google Scholar